Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
about
The role of HDAC6 in cancerClass IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactinHistone deacetylase inhibitors: Potential in cancer therapyEpigenetic Reprogramming of Muscle Progenitors: Inspiration for Clinical TherapiesCommon stemness regulators of embryonic and cancer stem cellsPolycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic ImplicationsTrials with 'epigenetic' drugs: an updateMitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse modelsHistone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell ViabilitySorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cellsSynergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivoVorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cellsEpigenetics in cancerDNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.CHK2 is involved in the p53-independent radiosensitizing effects of valproic acid.Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19bA phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumorsAn amino terminal phosphorylation motif regulates intranuclear compartmentalization of Olig2 in neural progenitor cells.Epigenetic Targeting of Transforming Growth Factor β Receptor II and Implications for Cancer TherapyHijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells.Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.Reciprocal epigenetic modification of histone H2B occurs in chromatin during apoptosis in vitro and in vivoHDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.Effect of EGF-induced HDAC6 activation on corneal epithelial wound healingOncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Inhibition and mechanism of HDAC8 revisited.Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells.Autophagy-regulating small molecules and their therapeutic applications.Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastomaHistone deacetylase: a potential therapeutic target for fibrotic disordersClass I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancerCombined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumorsEvaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomasHistone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe.Histone deacetylase 1 and 2 differentially regulate apoptosis by opposing effects on extracellular signal-regulated kinase 1/2
P2860
Q21296746-025AEDE4-94F6-41F2-A397-CCF8551D3AA3Q24322940-CA658543-AE5A-4012-AF49-0845754EB6C6Q24649025-2BA84342-7BEB-4210-B1D4-1DEA0CF9B444Q26770102-1A1638FA-340C-44EC-AA68-2F0AABE5BEE8Q26777882-4DFD002B-77FA-4FF7-82FF-3DC2956A0AEFQ26801380-20C24C07-DEEA-477C-A043-6D7DA21F5A32Q27000542-C83FA85F-4DFE-409C-B1BF-DC1452B551FEQ27310013-2DDEE7DE-3D80-4F13-A096-1F2E64479FCEQ27679266-F35387DE-F011-4E2A-8E95-8BD2A733A236Q28533484-C9625B99-2CEC-4CD9-9E09-2BC44A447149Q28741274-FCF8E64A-8609-4D69-ABC1-244D00B4CE5FQ28743758-7DE14078-82CC-4051-A86D-43AD395DC49FQ29617139-72D05C11-1AF5-44F8-AEBC-D9FE7783B856Q30931932-47A032F9-5E4D-4AB4-9F64-D40D83F3502CQ33400756-D7BF5C60-5333-4412-BAAA-C7FAFE5B26DAQ33410898-3B5B5211-47FA-405B-B36A-E8900B746C6DQ33597958-B6A5606F-6C5C-45AD-8226-303F27E59A2FQ33632244-3FF34085-7996-48B1-8B45-DF8B98A28013Q33752772-17209089-AAFF-4CF9-B75E-54C605460032Q33770410-7ACF7967-ABF4-477A-958B-E2CDDBB30010Q33802356-DDDF22B8-339F-4067-BC8D-91FC770018DEQ33831060-C56D40D1-6D7C-4E21-9945-AC12C1AF3E9AQ33831971-ABCF6AAB-2AF1-4964-8767-C3099724BCFBQ33838462-DF745B84-0F96-4290-95B9-12B0631A450CQ33842416-7D25D483-11FD-40CE-9AE5-BE7ED730D5B8Q33936620-E3D59D7B-FCCA-4986-8BB8-3A37DA6D7BF0Q33937865-97AC7BCE-5466-4F03-B00C-A1FA93228FB7Q33938181-FD017669-B48B-43A9-A805-75D9E4DEDEBBQ33995471-9E047B70-B3D4-426C-8962-082CB23B926CQ34074468-8840E18F-2B67-44A9-B0FE-0C5486CE32F8Q34114810-B109610C-1347-4CAB-9C32-E72839D511CDQ34147157-BB7EE8CC-33E4-43AC-BF5B-4A83C44E6FFEQ34171631-46027937-3164-47E0-A451-1F8537E7FD50Q34205125-994ED4D7-67FF-447F-90D6-1C659A9D8538Q34257607-6F413DBC-3B30-4CD0-B6B0-A8C49F50EF9BQ34318452-FD6393E3-70FB-441E-9C85-79AE9A59B498Q34372994-484DD559-B18C-4C5F-AE2D-82313F64835EQ34474267-A93C03DE-A20B-40B1-8CFD-24A3A3753032Q34541564-437DD191-105E-4EBA-8B83-B3E6678DC800Q34545336-5317775B-7682-406E-8245-5F0651EF7C32
P2860
Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Histone deacetylase inhibitors ...... in combination cancer therapy.
@en
Histone deacetylase inhibitors ...... in combination cancer therapy.
@nl
type
label
Histone deacetylase inhibitors ...... in combination cancer therapy.
@en
Histone deacetylase inhibitors ...... in combination cancer therapy.
@nl
prefLabel
Histone deacetylase inhibitors ...... in combination cancer therapy.
@en
Histone deacetylase inhibitors ...... in combination cancer therapy.
@nl
P2093
P1433
P1476
Histone deacetylase inhibitors ...... in combination cancer therapy.
@en
P2093
Francis J Giles
Jennifer S Carew
Steffan T Nawrocki
P356
10.1016/J.CANLET.2008.03.037
P407
P577
2008-05-06T00:00:00Z